Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nafamostat mesylate for VV-ECMO anticoagulation
NCT05555641Phase 2Unknown
- Start
- Dec 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Nafabelltan in critical illness, respiratory failure, cardiogenic shock. Status: unknown.
02
Drugs
Nafabelltan
03
Conditions
critical illnessrespiratory failurecardiogenic shock
Beyond the preview
Go deeper on NCT05555641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05555641.